JKDA 2021; 4(1): 5-9
Published online May 25, 2021
© Korean Society of Dialysis Access
윤상철
순천향대학교 부속 서울병원 외과학교실
Correspondence to : 윤상철
우 04401, 서울시 용산구 대사관로 59, 순천향대학교 부속 서울병원 외과학교실
Tel: 02-709-9243, Fax: 02-792-5976, E-mail: ys6325@schmc.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In terms of patency rate, complications, and maintenance costs, BaVT AVF using autogenous vein shows better results than AVG, so it is better to use BaVT AVF rather than AVG if possible. However, if the vein diameter is less than 2.5 mm or it is difficult to wait for a long maturation period, and if an arteriovenous fistula should be used early, the patient’s life expectancy is short, or if an arteriovenous fistula in the upper arm is considered secondary, AVG might be considered first. Korea’s arteriovenous fistula demographic environment is closer to Europe or Japan than the United States. The patient-centered approach recommended in this revised KDOQI guideline is important. However, I think that a recommendation based on the results and evidence of research conducted in an arteriovenous fistula environment similar to that of Korea is needed. In addition, since most of the recommendations in this update KDOQI guideline are based on expert opinions, a careful approach is needed rather than unconditionally acceptance.
Keywords Arteriovenous fistula, Basilic vein, Artificial graft
JKDA 2021; 4(1): 5-9
Published online May 25, 2021
Copyright © Korean Society of Dialysis Access.
윤상철
순천향대학교 부속 서울병원 외과학교실
Sangchul Yun
Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, Korea
Correspondence to:윤상철
우 04401, 서울시 용산구 대사관로 59, 순천향대학교 부속 서울병원 외과학교실
Tel: 02-709-9243, Fax: 02-792-5976, E-mail: ys6325@schmc.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
In terms of patency rate, complications, and maintenance costs, BaVT AVF using autogenous vein shows better results than AVG, so it is better to use BaVT AVF rather than AVG if possible. However, if the vein diameter is less than 2.5 mm or it is difficult to wait for a long maturation period, and if an arteriovenous fistula should be used early, the patient’s life expectancy is short, or if an arteriovenous fistula in the upper arm is considered secondary, AVG might be considered first. Korea’s arteriovenous fistula demographic environment is closer to Europe or Japan than the United States. The patient-centered approach recommended in this revised KDOQI guideline is important. However, I think that a recommendation based on the results and evidence of research conducted in an arteriovenous fistula environment similar to that of Korea is needed. In addition, since most of the recommendations in this update KDOQI guideline are based on expert opinions, a careful approach is needed rather than unconditionally acceptance.
Keywords: Arteriovenous fistula, Basilic vein, Artificial graft
Chanyeong Park, Suyoung Park
JKDA 2024; 7(2): 45-48 https://doi.org/10.56774/jkda24008Minsu Noh, Sang Jun Park, Hojong Park
JKDA 2024; 7(1): 12-18 https://doi.org/10.56774/jkda23012Jeeyoung Min, Sang Woo Park, Jin Ho Hwang
JKDA 2024; 7(1): 9-11 https://doi.org/10.56774/jkda24006